SAN DIEGO, May 27 /PRNewswire-FirstCall/ -- Protein Polymer Technologies,
Inc. (OTC Bulletin Board: PPTI) announces the election of the Company's Board
of Directors at its Annual Meeting of Shareholders.  Elected to initial terms
were William N. Plamondon III, Chief Executive Officer of Protein Polymer
Technologies, Inc., and James B. McCarthy, Chairman and CEO of the Gemini
Consulting Group, Inc.  Reelected to the Company's Board of Directors were:
Donald Kaplan, Ph.D., President and Chief Operating Officer, Protein Polymer
Technologies, Inc., Edward G. Cape, Ph.D. Kerry L. Kuhn, M.D., Steven M.
Lamon, Steve Peltzman, and J. Thomas Parmeter, Ph.D., Chairman, Protein
Polymer Technologies, Inc.  All Directors are elected to annual terms.
    Donald Kaplan, Ph.D. presented the company technical report which included
the status of the company's dermal product clinical testing.  He also updated
the status of negotiations with potential marketing partners for the tissue
sealant product, and reviewed the current standing of the company's IDN
product which has been licensed to Spine Wave.
    In other business, stockholders also ratified Peterson & Company, LLP, as
the Company's independent public accountants for the 2004 fiscal year.

    Protein Polymer Technologies, Inc., is a San Diego-based company focused
on developing bioactive products to improve medical and surgical outcomes.
From its inception in 1988, PPTI has been a pioneer in protein design and
synthesis, developing an extensive portfolio of proprietary biomaterials.
These genetically engineered biomaterials are high molecular weight proteins,
processed into products with physical and biological characteristics tailored
to specific clinical performance requirements.  Targeted products include
urethral bulking agents for the treatment of stress urinary incontinence,
dermal augmentation products for cosmetic and reconstructive surgery, surgical
adhesives for use in the repair of damaged spinal discs and as sealants in
pulmonary, bowel and cardiovascular surgery, scaffolds for wound healing and
tissue engineering, and depots for local drug delivery.  To date, PPTI has
been issued twenty-six U.S. Patents on its core technology with corresponding
issued and pending patents in key international markets.

    This press release contains forward-looking statements that are based on
management's views and expectations.  Actual results could differ materially
from those expressed here; further, the Company is not obligated to comment
specifically on those differences.  Risks associated with the Company's
activities include raising adequate capital to continue operations scientific
and product development uncertainties, competitive products and approaches,
continuing collaborative partnership interest and funding, regulatory testing
and approvals, and manufacturing scale up.  The reader is encouraged to refer
to the Company's 2004 Annual Report Form 10-KSB and 10KSB/A, and other recent
filings with the Securities and Exchange Commission, copies of which are
available from the Company, to further ascertain the risks associated with the
above statements.

Link to this page: